247 related articles for article (PubMed ID: 11935269)
41. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
[TBL] [Abstract][Full Text] [Related]
42. Regional mapping of prion proteins in brain.
Taraboulos A; Jendroska K; Serban D; Yang SL; DeArmond SJ; Prusiner SB
Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7620-4. PubMed ID: 1354357
[TBL] [Abstract][Full Text] [Related]
43. Valproic acid treatment results in increased accumulation of prion proteins.
Shaked GM; Engelstein R; Avraham I; Rosenmann H; Gabizon R
Ann Neurol; 2002 Oct; 52(4):416-20. PubMed ID: 12325069
[TBL] [Abstract][Full Text] [Related]
44. Proteinase K-sensitive disease-associated ovine prion protein revealed by conformation-dependent immunoassay.
Thackray AM; Hopkins L; Bujdoso R
Biochem J; 2007 Jan; 401(2):475-83. PubMed ID: 17018021
[TBL] [Abstract][Full Text] [Related]
45. Identification of a second bovine amyloidotic spongiform encephalopathy: molecular similarities with sporadic Creutzfeldt-Jakob disease.
Casalone C; Zanusso G; Acutis P; Ferrari S; Capucci L; Tagliavini F; Monaco S; Caramelli M
Proc Natl Acad Sci U S A; 2004 Mar; 101(9):3065-70. PubMed ID: 14970340
[TBL] [Abstract][Full Text] [Related]
46. Neuropathological spectrum of synucleinopathies.
Jellinger KA
Mov Disord; 2003 Sep; 18 Suppl 6():S2-12. PubMed ID: 14502650
[TBL] [Abstract][Full Text] [Related]
47. Toluidine blue-O staining of prion protein deposits.
Sánchez A; Guzmán A; Ortiz A; Rembao D; Espinosa B; Zenteno E; Guevara J
Histochem Cell Biol; 2001 Dec; 116(6):519-24. PubMed ID: 11810193
[TBL] [Abstract][Full Text] [Related]
48. Motif-grafted antibodies containing the replicative interface of cellular PrP are specific for PrPSc.
Moroncini G; Kanu N; Solforosi L; Abalos G; Telling GC; Head M; Ironside J; Brockes JP; Burton DR; Williamson RA
Proc Natl Acad Sci U S A; 2004 Jul; 101(28):10404-9. PubMed ID: 15240877
[TBL] [Abstract][Full Text] [Related]
49. The sequential development of abnormal prion protein accumulation in mice with Creutzfeldt-Jakob disease.
Muramoto T; Kitamoto T; Tateishi J; Goto I
Am J Pathol; 1992 Jun; 140(6):1411-20. PubMed ID: 1376559
[TBL] [Abstract][Full Text] [Related]
50. Human prion diseases: molecular and clinical aspects.
Glatzel M; Stoeck K; Seeger H; Lührs T; Aguzzi A
Arch Neurol; 2005 Apr; 62(4):545-52. PubMed ID: 15824251
[TBL] [Abstract][Full Text] [Related]
51. Curcumin binds to the alpha-helical intermediate and to the amyloid form of prion protein - a new mechanism for the inhibition of PrP(Sc) accumulation.
Hafner-Bratkovic I; Gaspersic J; Smid LM; Bresjanac M; Jerala R
J Neurochem; 2008 Mar; 104(6):1553-64. PubMed ID: 17996023
[TBL] [Abstract][Full Text] [Related]
52. Characterization of the role of dendritic cells in prion transfer to primary neurons.
Langevin C; Gousset K; Costanzo M; Richard-Le Goff O; Zurzolo C
Biochem J; 2010 Oct; 431(2):189-98. PubMed ID: 20670217
[TBL] [Abstract][Full Text] [Related]
53. Early destruction of the extracellular matrix around parvalbumin-immunoreactive interneurons in Creutzfeldt-Jakob disease.
Belichenko PV; Miklossy J; Belser B; Budka H; Celio MR
Neurobiol Dis; 1999 Aug; 6(4):269-79. PubMed ID: 10448054
[TBL] [Abstract][Full Text] [Related]
54. Astrocytes accumulate 4-hydroxynonenal adducts in murine scrapie and human Creutzfeldt-Jakob disease.
Andreoletti O; Levavasseur E; Uro-Coste E; Tabouret G; Sarradin P; Delisle MB; Berthon P; Salvayre R; Schelcher F; Negre-Salvayre A
Neurobiol Dis; 2002 Dec; 11(3):386-93. PubMed ID: 12586548
[TBL] [Abstract][Full Text] [Related]
55. Molecular mechanisms of prion pathogenesis.
Aguzzi A; Sigurdson C; Heikenwaelder M
Annu Rev Pathol; 2008; 3():11-40. PubMed ID: 18233951
[TBL] [Abstract][Full Text] [Related]
56. α-Synuclein Amyloids Hijack Prion Protein to Gain Cell Entry, Facilitate Cell-to-Cell Spreading and Block Prion Replication.
Aulić S; Masperone L; Narkiewicz J; Isopi E; Bistaffa E; Ambrosetti E; Pastore B; De Cecco E; Scaini D; Zago P; Moda F; Tagliavini F; Legname G
Sci Rep; 2017 Aug; 7(1):10050. PubMed ID: 28855681
[TBL] [Abstract][Full Text] [Related]
57. CNS pathogenesis of prion diseases.
Brandner S
Br Med Bull; 2003; 66():131-9. PubMed ID: 14522855
[TBL] [Abstract][Full Text] [Related]
58. Changes in the localization of brain prion proteins during scrapie infection.
DeArmond SJ; Mobley WC; DeMott DL; Barry RA; Beckstead JH; Prusiner SB
Neurology; 1987 Aug; 37(8):1271-80. PubMed ID: 3112607
[TBL] [Abstract][Full Text] [Related]
59. Sporadic Creutzfeldt-Jakob disease: the extent of microglia activation is dependent on the biochemical type of PrPSc.
Puoti G; Giaccone G; Mangieri M; Limido L; Fociani P; Zerbi P; Suardi S; Rossi G; Iussich S; Capobianco R; Di Fede G; Marcon G; Cotrufo R; Filippini G; Bugiani O; Tagliavini F
J Neuropathol Exp Neurol; 2005 Oct; 64(10):902-9. PubMed ID: 16215462
[TBL] [Abstract][Full Text] [Related]
60. The 139H scrapie agent produces hypothalamic neurotoxicity and pancreatic islet histopathology: electron microscopic studies.
Ye X; Scallet AC; Carp RI
Neurotoxicology; 1997; 18(2):533-45. PubMed ID: 9291501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
